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11
MMP Matrix metalloproteinase
MSCGM Mesenchymal stem cell growth medium
MSC Mesenchymal stem cells
mTOR Mammalian target of rapamycin






NOD/SCID Non-obese diabetic severe combined immunodeficiency mouse
iNOS/NOS2 Inducible nitric oxide synthase
NOV Nephroblastoma overexpressed
O2 Oxygen
OCT Optimum cutting temperature compound
RT-PCR Real-time reverse transcription polymerase chain reaction
PDGF Platelet derived growth factor







SDS Sodium dodecyl sulfate
SERPIN Serine protease inhibitor
SMC Smooth muscle cells
TCP Tricalcium phosphate
TEVG Tissue-engineered vascular graft
TLR Toll-like receptors
TNF Tumor necrosis factor
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The major hurdle in the survival of a tissue-engineered construct after implantation is 
vascularization. Pre-vascularization is one of the proposed methods to achieve 
vascularization in tissue-engineered constructs. This thesis is centered on pre-
vascularization of the tissue-engineered construct and local host response upon
implantation in vivo.
In Study I, mesenchymal stem cells (MSC) with and without endothelial cells (EC)
were cultured in normoxic and hypoxic conditions in vitro. The conditioned medium
from each group were evaluated with functional assays. The secretomes from hypoxic 
mono- and co-culture groups demonstrated increased wound healing and tube 
formation in vitro when compared with their normoxic counter-parts.
In Study II, pre-vascularized constructs were generated by co-culturing MSC and EC 
in three dimensional copolymer poly (LLA-co-DXO) scaffolds. After in vivo
implantation, local tissue response was evaluated with gene and protein analysis. The 
constructs with both MSC and EC were associated with decreased pro-inflammatory 
cytokines compared with those having MSC alone. 
In Study III, three-dimensional constructs with either MSC or EC alone were
implanted and their angiogenic and immunogenic property were evaluated. The 
expressions of anti-inflammatory and vasculogenic cytokines were higher in the 
constructs with EC than in the constructs with MSC. Furthermore, down-regulation 
of pro-inflammatory cytokines was observed.
In conclusion, MSC in combination with EC developed microvessels-like structures 
before implantation in vivo. Hypoxia, a common consequence after implantation of 
constructs, accelerated wound healing and tube formation via paracrine effect of
MSC. Combining these two effects might lead to inosculation and survival of a graft. 
Addition of EC improved the immunomodulatory property of MSC.
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In the field of tissue engineering, clinicians, scientists and engineers work together to 
develop functional substitutes to restore damaged tissues. Cells, signaling molecules, 
growth factors and scaffolds together hold the potential to generate new functional 
tissue. Tissue engineering as a field has grown quickly over the past decades, and is 
no longer confined to building artificial biological tissues in the laboratory. An
increasing number of clinical trials have been conducted, bringing tissue engineering 
closer towards establishing itself as a realistic treatment modality to enhance and 
restore the function of diseased and damaged tissues in patients (1, 2). In order to
reconstruct cranio-maxillofacial hard-tissue defects in humans, tissue-engineered 
constructs with autologous stem cells and resorbable scaffolds were implanted. Out of 
13 patients, 10 were successfully treated and hard-tissue formation was observed (3).
Treatment of patients with large bone defects however, still presents a challenge for 
clinicians.
Bone regeneration is a complex biological process comprised of a series of well-
orchestrated events. Bone grafting is a common clinical procedure in orthopedic and 
maxillofacial surgery and autologous bone grafts are currently considered as the ‘gold 
standard’ (4). The current approaches for bone replacement or enhancing bone 
regeneration are autologous bone grafts, but also include allografts and various bone 
substitute materials, with or without the addition of growth factors.
Synthetic or natural bone substitute materials can be used as alternatives to 
autologous and allogenic bone grafts, and in order to reconstruct large defects a
scaffold may be needed to restore its shape and size. A challenge in dealing with
large defects is the replacement of complex vascularized tissue.
The addition of another dimension, the mechanical environment, to the basic 3 point 
or triangular diagram used to illustrate the concept of tissue engineering (cells, 
biomaterials and signaling molecules) leads to the formation of a 4 point diamond 
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shaped structure (Fig. 1). This diamond structure has two V’s, which emphasize the 
importance of vascularization, and thus the need for a functional blood supply in 
tissue engineering. The diamond concept also indicates the importance of the host
response for successful tissue regeneration (5, 6).
Figure 1. Evolution of the diamond concept from the basic triangular concept. Figure 
inspired by (5, 6).
1.1.1 Rationale for vascularization
Every year millions of soft- and hard- tissue grafts are performed worldwide. The 
major challenge is in obtaining vascularization of the implant and its integration with 
the host vasculature (7, 8). The vascular system provides nutrients and oxygen and 
removes waste products from cells, tissues and organs via larger blood vessels which 
ultimately subdivide into small capillaries. The inter-capillary distance is between 
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150 and 200 μm, and cells remain alive by oxygen diffusion when they are within
this distance as shown in Fig. 2 (7, 9).
Figure 2. Schematic representation of inter-capillary distance, diffusion, and
transport to and from the tissue. Figure modified from (7).
Vascularization is a major determinant for success during healing, tissue regeneration 
and treatment of ischemic disorders. Blood vessels provide adequate oxygen for the
implanted constructs and aid in survival of the tissue-engineered constructs. The 
vascular system supplies nutrients and oxygen, removes waste products and acts as an
immune barrier against foreign bodies (10).
Cells in the epidermis of the skin, cartilage and cornea maintain their viability due to 
diffusion of oxygen and nutrients from adjacent blood vessels, and regeneration of 
these tissues has therefore been quite successful. In reconstruction of thicker and 
more complex tissues, an adequate blood supply is required for cell survival within 
the grafts. A major concern is to maintain perfusion of tissue-engineered 
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microvascular networks from in vitro culture conditions through the in vivo
conditions of a transplanted graft.
Vascularization of the implanted construct is needed to prevent graft necrosis and 
facilitate integration of the host vasculature with the graft. There are two main 
mechanisms for graft vascularization: inosculation and neovascularization. The term 
inosculation describes a coordinated process of anastomosis of the host vasculature to 
the capillaries within the graft (11, 12). Neovascularization is facilitated by a rapid
proliferation of endothelial cells (EC) into microvascular networks that undergo a 
maturation process required for the survival of the graft. 
1.1.2 Implantation of endothelial cells for vascularization
In 1999, the first clinical application of a tissue-engineered vascular graft (TEVG) 
was performed in a 4-year old child. The graft was prepared from autologous cells 
derived from a peripheral vein and seeded onto a tubular scaffold [50:50 copolymer 
of -polycaprolactone–polylactic acid reinforced with woven polyglycolic acid 
(PGA) fibers] (13). In 2001, a human trial was done to evaluate TEVG in patients 
with single ventricle physiology. Mononuclear cells from autologous bone marrow 
were seeded onto a biodegradable scaffold composed of PGA and -caprolactone/L-
lactide, and 25 grafts were implanted. Over a follow-up period of 6 years the study 
showed patent and intact grafts with successful vascular integrity (14). Asahara et al.
isolated endothelial progenitor cells (EPC) from peripheral blood vessels and 
demonstrated neovascularization (15), and since then extensive experimental and 
clinical research has been done. Pre-clinical and clinical studies have been performed
using EPC for the treatment of coronary artery diseases, demonstrating promising 
results (16, 17).
Vascular Development1.2
During embryonic development the vascular plexus is formed by two physiological 
mechanisms: vasculogenesis and angiogenesis. During early stages of embryogenesis, 
the vascular plexus is formed by differentiation of angioblasts or stem cells, termed 
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vasculogenesis. Angiogenesis is the formation of capillaries from pre-existing blood 
vessels (18). Vasculogenesis was previously thought to occur only in embryonic 
development, but it has now been shown that adult vasculogenesis is also possible
(15). Angiogenesis is either physiological or pathological. During wound healing and 
the ovarian cycle physiological angiogenesis takes place. Pathological angiogenesis 
occurs during tumor development, retinopathies, rheumatoid arthritis, psoriasis and in
development of hemangiomas (19, 20).
1.2.1 Vessel formation and maturation
Blood vessel formation is a dynamic process which includes proliferation of EC,
migration, lumen formation, branching, remodeling, pruning and recruitment of 
mural cells (21). The EC are normally in a quiescent state and get activated after 
receiving pro-angiogenic signals from vascular endothelial growth factor (VEGF), 
angiopoietin (ANG) and fibroblast growth factors (FGFs) (22). In the quiescent state, 
EC and pericytes share a common basement membrane. During the process of 
angiogenesis, the basement membrane is degraded by various proteolytic enzymes 
such as matrix metalloproteinases (MMP). The matrix degradation facilitates
migration and proliferation of EC and release of different growth factors needed for 
angiogenesis (23). The EC come in contact with the provisional extracellular matrix 
and this matrix supports proliferation of EC. Then, mural cells are recruited along 
with the re-establishment of extracellular matrix to stabilize the immature vessel (21).
It has been also reported that MSC could act as mural cells supporting EC to form 
microvascular networks (24).
1.2.2 Role of hypoxia in angiogenesis
Embryonic and developing tissues experience physiological hypoxia which results in 
angiogenesis. Hypoxia also occurs in wound healing, inflammation and tumor
formation (25). Limited oxygen supply leads to a hypoxic environment, which 
triggers the release of hypoxia inducible factors (HIF). The oxygen concentration 
determines the fate of HIF transcription and release of angiogenic molecules (26).
With normal oxygen concentration, HIF- hydroxylated by the prolyl-
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hydroxylase domain (PHD). Hydroxylated HIF is recognized by the von Hippel-
Lindau (VHL) tumor suppressor protein and is ubiquitinated. Finally, the 
ubiquitinated complex results in degradation of HIF- . However, under hypoxic 
conditions, hydroxylation of HIF- is inhibited, thus preventing degradation of HIF-
. As a result, HIF- accumulates and dimerizes with HIF- aryl hydrocarbon 
receptor nuclear translocator (ARNT) and binds to hypoxia-response elements 
(HRE). This transcription complex results in up-regulation of angiogenic factors (27)
(Fig. 3).
Figure 3. Regulation of hypoxia inducible factor (HIF) activity. Figure inspired by
(26).
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Pre-vascularization in Tissue Engineering1.3
1.3.1 Vascular scaffold
Microfabrication techniques such as soft-lithography, photo-lithography and 
micropatterning have been used to pre-treat the two-dimensional (2D) surface to 
allow cell adhesion and repulsion on the micrometer scale (28). Further, an 
elastomer-based capillary network created by micropatterning technique and then
seeded with EC has been used to generate tissue-engineered microvasculature (29). In 
addition, a network pattern created by optical lithography and patterned EC
transferred to extracellular matrix has been shown to generate a tubular structure, 
with functional vessels observed after implantation in vivo (30). These approaches,
however, were limited by the ability to only perfuse thin tissues. With recent 
advances, three-dimensional (3D) bio-printing has shown promising potential to 
engineer thick vascularized tissues. For example, a lumen size of 0.5-1mm was 
constructed by 3D printing, and EC and mural cells were introduced into those
vascular channels. Remodeling and maturation of the channel led to capillary network 
growth (31). EC printed into hydrogels were able to form a luminar network, with the
parameters of biological laser printing adjusted to guide the orientation and size of 
the networks (32). Production of vascular scaffolds in vitro is currently being studied 
by many in an effort to optimize vascularization in vivo.
1.3.2 In situ pre-vascularization
A pre-vascularized construct can be achieved using a three-step approach. First, the
scaffold is implanted into a well-vascularized and easily accessible part of the body to
generate a microvascular network, for example by subcutaneous implantation (33).
Then, the scaffold is excised after pre-vascularization and finally, the pre-
vascularized construct is transplanted into the defect site. Using this approach, the 
body acts as a natural bioreactor (34). However, this process is time-consuming and 
can be associated with unwanted ingrowth of granulation tissue onto the scaffold (33,
34). The reperfusion of the scaffold takes about 3-6 days and the pre-vascularized 
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construct can survive the first critical days after implantation until they are 
anastomosed with host vasculature (33).
Another approach is a flap technique where the scaffold is directly implanted to a
muscle where vascular ingrowth from the surrounding tissue can take place. The pre-
vascularized construct along with the entire free-flap is then transferred to the defect 
site and the vascular pedicle of the flap is surgically anastomosed to vessels at the site
of implantation (35-37). This process gives the opportunity to perfuse the construct 
from the time of implantation but results in a large defect at the donor site where the
pre-vascularized flap is generated (38).
Another approach, the arteriovenous (AV) loop technique, results in an intrinsic
vascularization where the center of the construct becomes vascularized first (39). The 
loop is placed inside a polycarbonate growth chamber with extracellular matrix to 
generate vascularized tissue, which can later be implanted and anastomosed to the 
defect site. The greatest advantage of this technique compared to the flap approach is 
the lack of morbidity at the donor site (40). The AV loop technique has been used to 
generate pre-vascularized bone to reconstruct a critical-size mandibular defect in
goats.  In this preclinical model, a -tricalcium phosphate/hydroxyapatite ( TCP/HA)
scaffold with AV-groove was created to allow direct anastomosis of the construct 
with facial vessels. This approach resulted in vascularized constructs and enhanced 
bone formation (41, 42).
1.3.3 Co-culture strategies
EC have widely been investigated aiming for pre-vascularized tissue-engineered 
constructs. However, autologous mature EC have some limitations. Isolation of tissue 
specific EC is relatively invasive, it can be difficult to harvest large number of cells 
and the cells may have a low proliferation rate in vitro (43). EPC can be isolated from 
bone marrow or peripheral blood, and can be cultured and expanded in vitro (44, 45).
They have been suggested as an alternative to mature EC.
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During angiogenesis EC interact with other cells, extracellular matrix and growth 
factors (21). EC and parenchymal cells interact during organogenesis (46).
Considering this natural process, researchers have started to make constructs where 
EC are co-cultured with different cells. This process has resulted in the assembly of 
EC to form vascular networks (47). EC co-cultured with dermal fibroblasts and 
keratinocytes have formed pre-vascularized skin grafts that demonstrated inosculation
after transplantation in vivo in a murine model (48). During this three-way
interaction, extracellular matrix is released by fibroblasts and EC can form capillary-
like structures within the matrix, while keratinocytes express VEGF and promote 
angiogenesis (49).
Mural cells are essential to provide the physical support needed for vessel
development, remodeling and stabilization (50). Co-culturing EC with mural 
precursor cells can generate long lasting stable microvascular networks.  For instance, 
microvascular networks created with this approach survived for 1 year in vivo,
whereas in the experimental group with only EC, the tissue-engineered micro-vessel 
regressed over time (51). Further, MSC and EC interact to form capillary-like
structures in Matrigel. There, MSC differentiate into smooth muscle cells and 
pericytes which facilitate extracellular matrix formation and vessel stabilization (52).
Co-seeding of MSC and EC can generate tissue-engineered constructs with an
intrinsic blood supply. Such pre-vascularized constructs can anastomose with the host 
vasculature after implantation in vivo (Fig. 4) (53, 54). MSC act as perivascular cells
and promote angiogenesis (24).
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Figure 4. Schematic diagrams of in-growth of host vasculature in tissue-engineered 
constructs without pre-vascularization by angiogenesis and interconnection of the 
pre-vascularized construct with host vasculature by inosculation. Figure modified
from (12).
Angiogenesis and Inflammation: Cause or Effect?1.4
Angiogenesis and inflammation are interrelated and share some common molecular 
pathways. After tissue injury, a cascade of molecular events occurs. The 
inflammatory markers activate resting EC to initiate angiogenesis. Activation of the 
Tie-2 receptor by ANG-1 down-regulates nuclear factor- NF- ), a transcription 
factor regulating inflammation. On the other hand, inflammatory molecules induce 
the release of ANG-2 by EC. ANG-2 binds to the Tie-2 receptor and up-regulates 
NF- . ANG-2 stimulates EC to produce VEGF for angiogenesis (55, 56). Similarly, 
macrophages play an important role during angiogenesis. Macrophages express the
Tie-2 receptor and release pro-angiogenic factors to initiate angiogenesis and 
anastomosis (57) (Fig. 5).
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Figure 5. Relationship between angiogenesis and inflammation. Figure based on (23,
57).
Host Response1.5
1.5.1 Inflammatory response after implantation of biomaterials
The basic function of biomaterials is to provide structural support to the defect area 
and facilitate tissue regeneration. Biomaterials may restore and augment the bio-
physical function of damaged and diseased hard and soft tissues following 
replacement and subsequent regeneration (58, 59). Synthetic biomaterials are foreign 
bodies to the host. However, implantation should not induce undesirable local or 
systemic effects, which is broadly termed as the biocompatibility of a material. The 
interaction between the scaffold and local tissue greatly influences the outcome of the 
therapy (60). A recent description of biocompatibility which includes both 
biomaterial and the host refers to an “intrinsically biocompatible system” described 
as being a property of the system and its effect on the material (61). The physical, 
chemical and mechanical properties of the biomaterial can also influence the host
response (62). A series of local events take place following implantation of a
biomaterial, potentially including tissue injury, blood-material interactions, 
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provisional matrix formation, acute inflammation, chronic inflammation, granulation 
tissue formation, foreign body reaction and fibrous capsule development (63, 64).
1.5.2 MSC and inflammatory niches
Adult stem cells are available in almost all parts of the body. MSC have been 
successfully isolated from bone marrow, adipose tissue, nervous tissue, amniotic 
fluid, umbilical cord, menstrual blood and dental pulps (65-67). MSC can 
differentiate into osteoblasts, chondrocytes, adipocytes, myocytes and neural-like
cells in specialized culture conditions (68, 69). An in vitro study revealed that MSC 
could also differentiate into endothelial-like cells (70). Intra myocardial injection of 
MSC in a chronic canine ischemic model resulted in MSC differentiation into EC and 
increased vascularity (71). Human MSC cultured in endothelial growth supplements,
under shear force and extracellular matrix stimuli showed endothelial-like properties. 
These endothelial-like MSC expressed endothelial markers CD31, VEGF receptor 2
and von Willebrand factor (72). However, MSC differentiation into the endothelial 
lineage is still controversial (73). Co-culture of MSC and EC can be utilized to create 
pre-vascularized tissue-engineered constructs which upon in vivo transplantation 
contains an intrinsic blood supply (53, 54, 74, 75). MSC not only differentiate into a
variety of tissue lineages but also have immunomodulatory properties (76) (Fig. 6).
Figure 6. Characteristics of MSC in vitro and in vivo. Figure modified from (76).
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Pericytes from capillaries, microvessels, adventitial cells and other blood vessels can 
produce MSC-like cells in vitro, cells that can differentiate into different cell lineages
(77). In addition to the differentiation potential of pericytes, like MSC they release 
different secretomes essential for tissue regeneration (78). Perivascular cells from 
different parts of the body in fact express the MSC surface markers CD44, CD73, 
CD90 and CD105 (79).
MSC are found generally in close proximity to blood vessels after implantation in 
vivo. They express the pericyte markers CD146+, CD34-, CD45- and CD56-. These 
facts support the concept that MSC are pericytes and blood vessels can act as a stem
cell niche (80). MSC secrete multiple bioactive molecules, which are activated after 
tissue injury. Like those from pericytes, these secretomes have tropic and 
immunomodulatory functions (81) (Fig. 7). However, although there are many 
similarities between MSC and pericytes, MSC can also be isolated from interstitial
tissues and tissues surrounding both arteries and veins, while pericytes are found 
localized on the basement membrane of capillaries (82, 83).
Figure 7. Microenvironment niche: from pericyte to activated MSC for regeneration 
and immunomodulation. Figure inspired from (81, 84).
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It has also been shown that not all MSC exhibit the properties of pericytes (85).
Pericytes differentiate into other cell lineages, are involved in inflammatory processes
and may be involved in the matrix formation process in wound healing. However, 
they do not accelerate wound healing in a similar manner to MSC (86).
The exact mechanism of MSC homing to a site of injury is still unclear. It has been 
proposed that after tissue injury, various cytokines are released and stimulate the 
newly migrated MSC to release growth factors. This microenvironment orchestrates
EC, fibroblasts, immune cells and inflammatory molecules as well as stem cells to 
promote angiogenesis. These changes locally result in the recruitment and 
differentiation of intrinsic MSC leading to tissue regeneration (87).
MSC are referred to as guardians of inflammation. After injury or infection a variety 
of pro-inflammatory cytokines are released from activated macrophages, which
activates MSC to secrete anti-inflammatory molecules and results in reduction of pro-
inflammatory molecules. MSC can thus suppress inflammation following tissue 
injury (88, 89).
The immunobiology of MSC is a double-edged sword. It has been reported that MSC
have both immunosuppressive and immune-enhancing properties depending on the
inflammatory status. That is, the inflammatory cytokine and chemokine levels
determine the immunomodulatory properties of MSC (87, 90). This bi-directional 
immune-regulatory function of MSC is illustrated in Fig. 8.
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Figure 8. Bidirectional immune-regulatory function of MSC. Figure based on (87).
Bioactive molecules for tissue regeneration are secreted in different amounts in 
response to the local microenvironment. There is no precise dose of bioactive 
molecules released and the exact amount of cytokines cannot be measured in vivo
(84). The inflammatory microenvironment regulates the secretion of bioactive 
molecules from MSC. The degree of inflammation determines the 
immunomodulatory properties of MSC, which is also associated with the initial
activation of MSC. A wide range of pro-inflammatory cytokines secreted by immune 
cells activates MSC (91) (Fig.9).
Pro-inflammatory cytokines such as tumor necrosis factor- TNF- ), interleukin-
or interleukin- IL- - ) in the presence of interferon- (IFN- ) induce
MSC to secrete increased levels of chemokines and inducible nitric oxide synthase 
(iNOS/NOS2). The cytokine induced iNOS produces nitric oxide (NO), which is an 
essential factor for T-cell suppression by MSC. However, although cytokine primed
MSC can attract T-cells, in the absence of NO there is an increase in the
inflammatory response (92). In response to tissue injury and released soluble factors 
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macrophages polarize into the classical M1 phenotype and the alternative M2. The 
M1 phenotype is pro-inflammatory and is stimulated by the toll-like receptors (TLR) 
ligand and IFN- , whereas the M2 phenotype is anti-inflammatory and activated by 
IL-4/IL-13, corresponding to polarization of T-cells into Th1 and Th2 (93) (Fig.10).
MSC may influence the polarization of macrophages by downregulating the 
production of pro-inflammatory cytokines and up-regulating the release of anti-
inflammatory cytokines. In a sepsis model, it has been shown that tumor necrosis 
factor receptor (TNFR) and TLR4-mediated NF- signaling upregulate synthesis of 
prostaglandin E2 (PGE2) by MSC. PGE2 binds to PGE2 receptors 2 and 4 (EP2 and 
EP4) in macrophages to produce IL-10. MSC ameliorate sepsis by inducing the 
production of IL-10 by macrophages and alternatively activating M2 macrophages
(94).
Figure 9. Schematic representation of the stages in wound healing: inflammatory 
phase, reparative phase and remodeling phase. The degree of inflammation 
determines the fate of MSC activity. Figure modified from (91).
1.5.3 Modulation of MSC via TLR
TLR are expressed by MSC at the mRNA and protein levels. TLRs 1, 2, 3, 4, 5 and 6 
are expressed at the mRNA level and TLRs 2, 3, 4, 7 and 9 are expressed at the
protein level (95). TLR stimulation of MSC not only takes part in immune-
modulation but also activates survival, proliferation, migration and differentiation of 
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MSC. TLR activation in MSC may be initiated either by MyD88 dependent or 
independent signaling. This signal cascade results in downstream activation of NF-
, resulting in secretion of different TLR, cytokines and
chemokines (96). MSC isolated from MyD88 knock out mice failed to differentiate 
into osteocytes and chondrocytes, suggesting the importance of TLR and their ligands 
in directing the fate of MSC (97). MSC treated with TLR ligands showed increased 
migration in a transwell system compared to non-treated MSC, while pretreatment 
with anti-TLR3 antibodies prior to ligand activation inhibited MSC migration. This 
demonstrated that MSC migration is dependent on the presence of TLR3 (98).




Survival of MSC after implantation is critical, although the long term effect is 
dependent on the residing MSC. Therefore, it is important to recruit the resident MSC
while simultaneously ensuring survival of the graft. In large grafts the main obstacle 
is angiogenesis, with the host vasculature unable to perfuse the tissue-engineered 
constructs immediately after implantation. A pre-vascularized graft is therefore 
needed to meet this requirement and to keep the implanted MSC-construct viable and 
facilitate its role in tissue regeneration.
Different co-culture strategies have been employed to increase the osteogenic and 
vasculogenic properties of MSC. Co-culture of MSC and EC has been used for pre-
vascularization of tissue-engineered constructs (47). Inflammatory cytokines and 
hypoxia can stimulate MSC to produce different growth factors, and these secretomes 
have direct effects on endothelial cells and fibroblasts promoting both angiogenesis 
and wound healing. 
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2. AIMS
The fundamental concept in vascular tissue engineering is to provide sufficient 
vascularity to the implanted construct. Basically, adequacy of blood supply 
determines the fate of the tissue-engineered construct.
The main focus of this thesis was to determine the local tissue response to the tissue 
engineered constructs.
The thesis is based on the following specific aims:
1. To study the effect of MSC and MSC/EC on wound healing and vessel formation 
in vitro under hypoxic conditions (Study I)
2. To assess the influence of pre-vascularized constructs on leukocyte transmigration 
in vivo (Study II)
3. To evaluate the in vivo host response and vessel formation after implantation of 
MSC and EC (Study III)
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Figure 11a. Schematic summary of the study design.
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The studies I, II and III are schematically illustrated in Fig. 11a and 11b. Study I, II 
and III corresponds to paper 1, 2 and 3 respectively.
Cell Culture (Studies I-III)3.1
Primary human bone marrow derived MSC were purchased from Lonza 
(Walkersville, Maryland, United States) and expanded in Mesenchymal Stem Cell 
Growth Medium (MSCGM™) SingleQuots™ (Lonza) containing mesenchymal stem 
cell basal medium supplemented with mesenchymal cell growth supplement 
(MCGS), L-glutamine and GA-1000 (Gentamicin, Amphotericin-B) (Study I).
Figure 11b. Schematic summary of the study design.
Study II
Phase 2 Study III
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Primary human bone marrow derived MSC were purchased from StemCell 
Technologies (Vancouver, British Columbia, Canada) and cultured in MesenCult®
complete medium (StemCell Technologies) following the manufacturer’s instructions 
(Studies II and III).
Human umbilical vein endothelial cells (EC) were purchased from Lonza 
(Walkersville, Maryland, United States) and were cultured in Endothelial Cell 
Growth Medium (EGM) (Lonza) following the manufacturer’s instructions (Studies I 
- III).
3.1.1 Co-culture of MSC and EC (Studies I and II)
MSC and EC were co-cultured in a 5:1 ratio to conduct Studies I and II. In Study I
MSC and EC were separated using CD31 Endothelial Cell Dynabeads® (Invitrogen, 
Carlsbad, California, United States) according to the manufacturer’s instructions.
3.1.2 Hypoxic Chamber (Study I)
A Modular Incubator Chamber (MIC-101) (Billups-Rothenberg Inc. Del Mar, 
California, United States) was used as a hypoxia chamber. First, the chamber was 
flushed and filled with a gas mixture of 1% O2, 5% CO2 and 94% N2 and then placed 
inside the incubator.
Scaffolds (Studies II and III)3.2
3.2.1 Fabrication of scaffolds
Poly (L-Lactide-co-1, 5dioxepan-2-one) [poly (LLA-co-DXO)] scaffolds were used 
in Studies II and III and were prepared as previously described (99, 100). Briefly, 
porous scaffolds with a dimension of 12 mm diameter, 1.5 mm thickness and pore 
sizes of 90-500 μm were produced from co-polymer poly (LLA-co-DXO) by a 
solvent-casting particulate-leaching method. The sterilization of scaffolds was carried 
out in a pulsed electron accelerator operating at 6.5 MeV (Mikrotron, 
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Acceleratorteknik, The Royal Institute of Technology, Stockholm, Sweden) with 
radiation dose of 2.5 Mrad in an inert atmosphere.
3.2.2 Preparation of scaffolds 
The scaffolds were pre-seeded with cells before in vivo implantation and were treated 
as previously described (54, 101). Briefly, the scaffolds were pre-wet with complete 
medium and incubated overnight at 37 °C and 5 % CO . The next day, cells were 
seeded and allowed to attach overnight. An orbital shaker (Eppendorf®, Hamburg, 
Germany) was used in order to facilitate homogeneous distribution of cells. The 
following day, scaffolds were transferred to separate modified spinner flasks 
(Wheaton Science, Millville, New Jersey, United States) for 1 week in a dynamic 
culture system with 50 rotations per minute. After 1 week culture in vitro, 6 mm discs 
were punched from the center of the scaffold with a dermal skin punch and then 
implanted in vivo (Fig. 12).
Figure 12. A macroscopic image of the poly (LLA-co-DXO) scaffold before cell 
seeding and implantation in vivo.
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Animal Procedures (Subcutaneous mouse model) 3.3
(Studies II and III)
Non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice were used 
in Studies II and III. They were purchased from Taconic Farms (Bomholtgård 
Breeding and Research Center, Ry, Denmark). On the back of the mice an incision 
was made and subcutaneous pouches were created with blunt dissection which 
provided sufficient space for implantation of the scaffolds. Wounds were closed with 
Vetbond™ Tissue Adhesive (n-butyl cyanoacrylate) (3M™, St. Paul, Minnesota, 
United States). After 3 weeks’ implantation, animals were euthanized with deep 
Isoflurane (Schering Plough, Kenilworth, New Jersey, United States) anesthesia 
followed by cervical dislocation and cell/scaffold constructs were dissected and 
retrieved. The samples were then divided and further processed for analysis.
Gene Profiling3.4
3.4.1 Real-time RT-PCR (Studies I-III)
An E.Z.N.A.® Total RNA Kit (Omega Bio-Tek, Norcross, Georgia, United States) 
was used to isolate the RNA from the samples (Study II and III). In Study I, a
Maxwell® 16 LEV simplyRNA Cells Kit (Promega Corporation, Madison, 
Winconsin, United States) was used for RNA isolation. A NanoDrop 
Spectrophotometer (ThermoScientific NanoDrop Technologies, Wilmington, 
Delaware, United States) was used to quantify and evaluate RNA purity. A total of 
1000 ng of the total RNA was reverse transcribed to cDNA using a cDNA kit 
(Applied Biosystems, Carlsbad, California, United States). Real-time reverse 
transcription polymerase chain reaction (Real-time RT-PCR) was performed on a 
StepOnePlus™ real time PCR system (Applied Biosystems). TaqMan® gene
expression assays (Applied Biosystem) were applied in all studies. GAPDH was used
as endogenous control and data analysis was performed with a comparative Ct 
method (102).
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Table 1. Overview of gene expression assays.
Assay ID Full name Gene 
Symbol
Species Study
Hs99999905_m1 Glyceraldehyde 3-phosphate 
dehydrogenase
GAPDH Human I
Hs01555410_m1 Interleukin-1 IL- Human I
Hs00985639_m1 Interleukin-6 IL-6 Human I
Hs00174103_m1 Interleukin-8 IL-8 Human I
Hs00961622_m1 Interleukin-10 IL-10 Human I
Hs00900055_m1 Vascular endothelial growth 
factor-A
VEGF-A Human I
Hs00966526_m1 Platelet derived growth factor PDGF Human I
Hs00266645_m1 Fibroblast growth factor FGF Human I
Hs00375822_m1 Angiopoietin-1 ANG-1 Human I
Hs01048042_m1 Angiopoietin-2 ANG-2 Human I
Hs00171022_m1 Chemokine ligand 12 CXCL12 Human I
VIC MGB Glyceraldehyde 3-phosphate 
dehydrogenase
GAPDH Mouse II,III
Mm 00443260_g1 Tumor necrosis factor TNF Mouse II,III
Mm 00434228_m1 Interleukin-1 IL-1 Mouse II,III
Mm 00446190_m1 Interleukin-6 IL-6 Mouse II,III
Mm 00445259_m1 Interleukin-4 IL-4 Mouse II,III
Mm 00439614_m1 Interleukin-10 IL-10 Mouse II,III
Mm 00440502_m1 Inducible nitric oxide synthase 2 iNOS
(NOS2)
Mouse II,III
Mm 00468869_m1 Hypoxia inducible factor-1 HIF- Mouse II,III
Mm 00507836_m1 Hypoxia inducible factor- HIF-
(ARNT)
Mouse II,III
Mm 0044968_m1 Mammalian target of rapamycin mTOR Mouse II,III
PCR Array (Study III)
Mouse TLR pathway Rt2 Profiler PCR arrays (SuperArray Bioscience, Frederick, 
Maryland, United States) were performed. An Rt2 PCR array First Strand Kit 
(SuperArray Bioscience) was used for cDNA synthesis. PCR array was done on a 
StepOnePlus™ real-time PCR system (Applied Biosystem) with Rt2 Real-time SyBR 
Green/Rox PCR mix (SuperArray Bioscience). 
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3.4.2 Microarray (Study II)
The gene expression profile of MSC co-cultured with EC in vitro was previously 
published by our group (103) and the microarray data obtained from this study was 
further analyzed by J-Express 2009 software (104). A set of inflammatory genes were 
submitted to the DAVID database and the pathways were determined by KEGG 
pathway mapping (105).
Protein Isolation (Studies II and III)3.5
The organic phase during RNA isolation was preserved at -80°C. Protein isolation 
was performed following the protocol of Chomczynski (106). Isopropanol was added 
to the organic phase and a precipitate was formed. The precipitate was washed with 
ethanol for five minutes and the process was repeated three times. After washing, the 
precipitate was dissolved in 0.5% sodium dodecyl sulphate (SDS) solution.  
Quantifications and determination of protein purity was performed with a NanoDrop 
Spectrophotometer (ThermoScientific NanoDrop Technologies).
Western Blotting (Studies II and III)3.6
After measuring the protein concentration, 30 μg of total protein was mixed with 4X 
Laemmli sample buffer (Bio-Rad laboratories, Hercules, California, United States) 
and loaded on 4-15 % Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad) for 
electrophoresis and transferred to PVDF transfer membranes (TRANS-Blot® 
Turbo™ System, Bio-Rad). The membranes were blocked in 5% BSA/TBST and 
incubated with primary antibodies (in 5% skimmed milk/TBST) as presented in Table 
2 at 4°C overnight. After three washes with TBST, the membranes were incubated 
with appropriate secondary antibody (in 5% skimmed milk/TBST) as listed in Table 2 
for 1 h. Immunoblotting bands were visualized by Immun-Star™ WesternC™ 
Chemiluminescence Kits and a Gel Doc™ EZ System (Bio-Rad) was used for 
imaging and protein-band assay.
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Table 2. Overview of western blotting.
Abbreviation Full name Species Manufacturer Study
GAPDH Glyceraldehyde 3-phosphate 
dehydrogenase
Mouse Santa Cruz II,III
IL-1 Interleukin-1 Mouse Abcam II
IL-6 Interleukin-6 Mouse Abcam II
HIF- Hypoxia inducible factor-1 Mouse Santa Cruz III
HIF- Hypoxia inducible factor- Mouse Santa Cruz III
Proteome Profiling (Study III)3.7
The Mouse Angiogenesis Array Kit (R&D Systems, Inc., Minneapolis, Minnesota, 
United States) was used to detect the expression of 53 angiogenesis related proteins. 
The Proteome Profiler Array was performed according to the manufacturer's protocol. 
Briefly, 100 μg of total protein was mixed with a cocktail of biotinylated detection 
antibodies and then incubated with a nitrocellulose membrane spotted with capture 
antibodies in duplicate. Protein-detection antibodies bound to the capture antibody 
were detected using Streptavidin-HRP and chemiluminescent detection reagents.  The 
Gel Doc™ EZ System (Bio-Rad) was used for imaging. The mean spot pixel density 
was quantified using image software analysis.
ELISA (Study I)3.8
The enzyme-linked immunosorbent assay kit (ELISA) (R&D Systems, Minneapolis, 
Minnesota, United States) was used to measure the concentration of VEGF-A in the 
samples, following the manufacturer’s instructions. Optical densities were determined 
using FLUOstar OPTIMA microplate reader (BMG LABTECH, Ortenberg, 
Germany).
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Tissue staining and imaging (Studies II and III)3.9
3.9.1 Tissue Preparation
The samples intended for cryosectioning were immediately embedded in optimal 
cutting temperature compound (Tissue-Tek® O.C.T., Sakura Finetek, Tokyo, Japan) 
and kept at -80°C. Samples intended for paraffin sectioning were fixed in 4% 
paraformaldehyde. The frozen samples were sectioned with a Leica CM 3050S (Leica 
Microsystems, Wetzlar, Germany) at -
paraffin- embedded samples were sectioned with a microtome (Leica). 
3.9.2 Histological staining
Tissue staining was done as described in paper 2 and 3. The overview of the staining 
is presented in Table 3.
Table 3. Overview of histological staining.
Abbreviation Full name Species Manufacturer Study
IL-1 Interleukin-1 Mouse Abcam II,III
IL-6 Interleukin-6 Mouse Abcam II,III
NIMP Neutrophil antibody Mouse Abcam II,III
CD11b Cluster of differentiation 11b Mouse BD II,III
CD31 Cluster of differentiation 31 Mouse BD III
HE Hematoxylin and eosin Non-specific II
3.9.3 Quantification of immunostaining
In Studies II and III, 5 sections from one scaffold were mounted on each slide. Each 
section on the slides was divided onto 5 measuring grids starting from top to bottom 
in the vertical direction (Fig. 13). The 5 sections on each slide (average for the 
mouse) and 5 measuring grids in each section (average for the section) were used for 
image quantification. Images were made with a Zeiss Axiovision 4.8.1 (Toronto, 
Ontario, Canada) and the files were exported as JPEG standard.
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Figure 13. Schematic representation showing measuring grids for quantification.
Wound healing assay (Study I)3.10
Approximately 30,000 EC/well were seeded in Culture-Insert 24 (80241, ibidi, 
Martinsried, Germany) until they were confluent. The inserts were removed and a
monolayer wound was created. The cells were incubated with conditioned medium 
from hypoxic and normoxic groups and compared to EGM as positive control and 
vehicle media as negative control. Images were made at different time intervals (3, 6, 
12, 18 and 24 h) with a Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan) at 4x 
magnification using phase contrast mode. The surface area of the wound was 
calculated with NIS elements AR 3.2 software (NIS elements, Tokyo, Japan). The 
overview of wound healing assay is illustrated in Fig. 14.
Figure 14. Steps in the wound healing assay (modified from ibidi.com).
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Tube formation assay (Study I)3.11
Growth Factor Reduced MatrigelTM (BD Biosciences, San Jose, California, United 
States) was added to 96 well-plates and incubated to solidify. EC were suspended in 
the conditioned medium from hypoxic and normoxic groups and compared to EGM
and vehicle media. The EC were seeded onto the solidified matrigel. After 6 h, tube 
formation was observed and images were made. The tube formation was quantified 
with the ImageJ software program (NIH, Bethesda, Maryland, United States) with the 
Angiogenesis Analyzer plugin (107). The schematic representation of the tube 
formation assay is shown in Fig. 15.
Figure 15. Steps in the tube formation assay.
Statistical Analysis (Studies I-III)3.12
The significance level was set to p<0.05 for all statistical analysis. SPSS Statistics 21 
(IBM, Armonk, New York, USA) was applied for statistical processing and analysis. 
Two groups were compared with the independent samples t-test, whereas a multiple 
comparison one-way ANOVA was performed to compare three or more experimental 
groups.
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4. RESULTS AND SUMMARY OF PAPERS
Hypoxia preconditioning of MSC (Study I)4.1
4.1.1 Hypoxia increased VEGF expression 
Study I evaluated the effect of hypoxic culture conditions on MSC. The influence of 
hypoxia was assessed in both mono- and co-culture groups. The gene expression of 
VEGF-A was significantly higher in the hypoxic groups compared to the normoxic 
groups after 12 h incubation. After 48 h incubation, the protein level was relatively 
higher in hypoxic groups compared to the normoxic groups and the difference was 
statistically significant.
4.1.2 Hypoxia accelerated wound healing
The conditioned medium from hypoxic groups (HMSC and HMSC/EC) showed 
accelerated wound healing compared to normoxic groups in vitro. The wounded area 
was completely closed by 12 h in the positive control group. The cell-free area was 
completely filled with migrated cells within 18 h in HMSC and HMSC/EC groups. 
All groups were normalized to baseline data at time point 0 h.
4.1.3 Hypoxia increased vessel formation
The EC started to form tube-like structures within 6 h in the positive control medium. 
The tube formation in different experimental groups was normalized with vehicle 
medium as controls. The tube-like structures were quantified for various parameters 
such as number of nodes, meshes, segments and total lengths (108). The hypoxic 
groups exhibited more tube-like structures compared to their normoxic counterparts.
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Host cell migration into the construct4.2
The seeding efficiency of both MSC and EC in the scaffold was evaluated in vitro
using the following equation (109).
Seeding efficiency of the cells:  (1        ) ×100
Both MSC and EC showed similar seeding efficiency (Study III). The native mouse 
cell infiltration into the constructs was evaluated at 1 and 3 weeks in vivo. The total 
number of migrating cells into the construct was higher at 3 weeks. The HE staining 
showed recruitment of inflammatory cells in relation to the scaffold and their 
increased progression over time (Study II).
Leukocyte transmigration into the pre-vascularized4.3
construct (Study II)
Study II assessed the influence of EC on leukocyte transmigration. The DAVID 
pathway database (105) showed that multiple genes related to the TLR signaling 
pathway and the leukocyte transendothelial migration pathway were differentially 
regulated in the co-culture group compared to the mono-culture group in vitro.
Further, RT-PCR of mouse specific genes was performed for in vivo week 1 and 3 
samples for selected biomarkers related to hypoxia and inflammation. Among all the 
selected markers, only IL- (p<0.001) down-regulated in the 
MSC/EC group compared to the MSC group after 1 week of implantation. After 3 
weeks’ implantation all the markers were highly up-regulated in the MSC and 
MSC/EC groups compared to scaffolds implanted without cells. IL- (p<0.001) and 
IL-6 (p<0.05) were significantly down-regulated in the MSC/EC group compared to 
the MSC group. NOS2, mTOR, HIF- - -regulated in the 
MSC/EC group compared to the MSC group.
After 3 weeks’ implantation the scaffolds were retrieved and immunofluorescence 
double staining and western blotting was performed to evaluate the association 
between inflammatory cytokines and migrating inflammatory cells. The number of 
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neutrophils was markedly higher in the co-culture constructs (p<0.001). However, IL-
the MSC/EC group compared to the MSC group. Both 
neutrophils and IL- present in significantly higher numbers in 
mono- and co-culture constructs compared with construct implanted without cells.
Monocyte derived cells were co-stained with IL-6 and CD11b. The number of co-
stained cells was significantly higher in MSC and MSC/EC constructs compared with 
control construct implanted without cells. IL-6 and CD11b positive cells were 
significantly less in the group with added EC compared to MSC alone. Protein 
expression of IL- -6 were lower in the co-culture group compared to the 
monoculture group.
Effects of MSC and EC on host response and 4.4
vascularization (Study III)
The mouse TLR pathway was evaluated after 3 weeks’ implantation. Out of 84 genes, 
49 were down-regulated in the EC group compared to the MSC group. Additionally, 
RT-PCR for pro- and anti-inflammatory cytokines was performed. The gene 
expression of IL- -6 were significantly lower in the EC group compared to 
the MSC group. On the other hand, IL-10 expression was higher in the EC group 
compared to the MSC group. To investigate the recruitment of acute and chronic 
inflammatory cells in relation to the scaffold, double staining was performed. The 
number of neutrophils was markedly higher in EC constructs compared to MSC 
constructs, although IL- in MSC constructs.
Double stained cells with CD11b and IL-6 were fewer in EC compared to MSC 
constructs.
The mRNA of hypoxia related genes were investigated to evaluate the response to 
hypoxia after 3 weeks’ implantation of MSC and EC constructs. The gene expression 
of HIF- - 2 and mTOR were significantly higher in the EC group 
compared to the MSC group. However, protein expression of HIF-
the EC group compared to the MSC group whereas the expression of HIF-
higher in the EC group compared to the MSC group. The increase in hypoxia related 
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genes could lead to increased angiogenesis. To assess the angiogenic property, 
angiogenic proteome profiling was performed. Out of 53 proteins, 10 were highly 
regulated. The proteins related to vascular growth were increased in EC constructs
compared to MSC constructs. Additionally, the total vessel area fraction was 
quantified to evaluate the influence of implanted cells on vascularization. The CD31 
immunostaining of the vessels showed that EC constructs had a higher blood vessel 
density compared to MSC constructs.
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5. DISCUSSION
The field of tissue engineering has grown greatly in the past few decades. Advances 
in tissue engineering have improved the treatment modalities of different diseases.
However, vascularization of tissue-engineered constructs remains a challenge in the
field of regenerative medicine. Inflammation, vascularization and regeneration are 
interrelated processes with major roles in tissue engineering. MSC are widely studied 
for their regenerative potential, as are EC for vascular regeneration. Taking into 
account the potential of both the cell types, an effort has been made by our group to
grow both the cells together, and this co-culture system has been used to generate 
pre-vascularized constructs (54). After implantation of the tissue-engineered 
construct, implanted cells experience hypoxia until native vascularization to the 
construct is achieved and regeneration is achieved (110).
Hypoxia accelerates wound healing5.1
Hypoxic conditions release cytokines and chemokines to maintain homeostasis in the 
tissue. With hypoxia, oxygen tension decreases resulting in accumulation of 
transcription factor HIF, which leads in turn to transcription of genes related to 
angiogenesis, cell proliferation, cell migration, cell survival and apoptosis (111, 112).
Hypoxia also mediates inflammation and the inflammatory microenvironment is 
highly metabolic with increased oxygen consumption as a result (113, 114). The 
paracrine effects of MSC have been widely studied in the inflammatory environment, 
and it has been shown that they can induce wound healing and tissue regeneration 
(115). The conditioned medium resulting from hypoxic preconditioning of MSC 
expressed different cytokines and extracellular matrix proteins components than from 
non-hypoxic cells (116, 117). Hypoxia preconditioning of cells derived from other 
sources than bone marrow was found to influence the expression of cytokines and 
chemokines promoting wound healing and angiogenesis. In a distraction osteogenesis 
mice model, application of hypoxic conditioned medium demonstrated improved 
bone healing compared to normoxic conditioned medium (118). The in vitro results 
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presented in Study I, demonstrated that the conditioned medium from hypoxic 
culture groups accelerated wound healing. These finding are in accordance with a
previous study where hypoxic conditioned medium from MSC improved wound 
healing in a murine model in vivo (119).
Hypoxia regulates angiogenesis5.2
Vascularization is the most essential factor for survival of the implanted tissue-
engineered construct. VEGF-A is a pro-angiogenic factor, expressed by MSC under
normal culture conditions, and the expression is dependent on differentiation of MSC 
(120). It has been shown that MSC express more VEGF-A than do EC in vitro under
normoxic conditions (24). Further, the conditioned medium obtained from MSC 
under hypoxic conditions was enriched with different cytokines and chemokines than 
from MSC under normoxic conditions (121). In order to examine the effect of 
hypoxia on the implanted cells in Study II and Study III, an in vitro experiment was 
first performed (Study I), where the cells were exposed to short-term hypoxic 
condition. With a normal oxygen concentration, the HIF- ubiquitinated and 
degraded. However, during hypoxia, HIF- and forms a heterodimer 
with HIF- resulting in transcription of angiogenic genes such as VEGF-A (111,
122). After hypoxia, we observed that the expression of VEGF-A was higher in 
HMSC and HMSC/EC groups and the expression was independent of the addition of 
EC. Several studies have shown that hypoxic preconditioning of MSC resulted in 
increased VEGF-A expression (119). The hypoxic preconditioning of MSC activated 
the PI3K-AKT pathway and increased phosphorylation of Akt, which is known to 
regulate angiogenesis (121). Study I demonstrated that the preconditioning of MSC 
with hypoxia improved angiogenesis. 
mTOR, a central regulator of cell proliferation, cell metabolism and angiogenesis,
modulates the expression of VEGF-A and NO (123). A study done in human 
osteoblasts showed that cell proliferation and angiogenesis was suppressed via 
inhibition of the PI3K/AKT/mTOR pathway (124).  Endothelial sprout formation was 
promoted under hypoxia but after addition of mTOR inhibitor, angiogenesis was 
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reduced, whereas overexpression of mTOR restored hypoxia and induced 
angiogenesis (125). The mRNA expression of mTOR was higher in MSC/EC and EC 
constructs in the studies presented here (Studies II and III). The generation of pre-
vascularized constructs with MSC and EC co-culture in vitro before implantation in 
vivo (Study II) and the paracrine factors released by MSC under a hypoxic 
environment during healing may improve inosculation of pre-vascularized constructs 
with the surrounding microenvironment. 
In Studies II and III, tissue hypoxia after implantation of the construct was observed. 
Hypoxia inducible factors were more highly expressed in constructs with EC. The up-
regulation of HIF genes are known to increase angiogenesis. The initiation of 
angiogenesis resulted in lower HIF- the EC group in Study III.
The HIF- , whereas
HIF- (126). Hypoxia induces the expression 
of NOS2. The expression of NOS2 was up-regulated in a chronic hypoxia rat model 
where rats were kept under hypoxic conditions for 3 weeks (127, 128). NO generated 
by NOS2 promotes the accumulation of HIF- -
-A (129). NOS2 promotes wound 
healing, regulates angiogenesis and tissue repair. Incisional and excisional cutaneous 
wound healing angiogenesis was reduced in NOS2 knockout mice (130). The mRNA 
expression of NOS2 was higher in MSC/EC and EC constructs compared to MSC 
constructs, inducing angiogenesis. We also observed that expression of angiogenic 
markers was increased in MSC constructs compared to constructs without cells. 
Tissue hypoxia after implantation may have promoted angiogenic gene expression 
from MSC, as we have shown that MSC under hypoxic conditions enhance wound 
healing and angiogenesis compared to MSC under normoxia (Study I). Different 
angiogenic proteins were analyzed to compare the angiogenic activity of MSC and 
EC in vivo (Study III). The release of pro-angiogenic proteins were comparatively 
higher in EC constructs compared to MSC constructs, whereas the release of anti-
angiogenic factor was higher in MSC constructs. CD31 immunostaining of 
histological samples after 3 weeks’ in vivo implantation showed increased vessel
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formation in the EC group and this result correlates with the increased expression of 
pro-angiogenic factors by EC.
Inflammatory reaction after implantation of tissue-5.3
engineered constructs
The release of inflammatory cytokines promotes vascularization and regeneration. 
The favorable balance between pro- and anti- inflammatory cytokines induces tissue
organization and regeneration (131, 132). In vivo Studies II and III were carried out 
in order to investigate the early host response after implantation of tissue-engineered 
constructs with human cells. A moderately immunocompromised murine model was
chosen. NOD/SCID mice are unable to perform VDJ (variable, diversity, and joining 
genes) recombination and subsequent antibody production but can produce 
monocyte-derived cells and neutrophils, and thus are able to induce the early immune 
response (133). The seeding efficacy of the MSC and EC was similar on the scaffolds
(Study III). A gradual increase in the number of host (mouse) cells infiltrating into 
the construct was noticed from 1 to 3 weeks of implantation in vivo (Study II).
Similar observations were illustrated from day 1 to day 28 in a PriMatrix implant 
subcutaneous mice model (134).
5.3.1 EC altered the TLR expression of MSC 
It has been shown that MSC express various genes related to the TLR pathway and 
may have a role in immunomodulation. TLR priming of MSC results in two active 
phenotypes, MSC1 and MSC2. Two TLR are mainly involved in this process, TLR4 
and TLR3. TLR4-primed MSC (MSC1) and TLR3-primed MSC (MSC2) regulate 
pro-and anti-inflammatory cytokines respectively (135). TLR activation in MSC can 
induce NF- - -6, IL-8/CXCL8, 
CXCL10 and CCL5, which results in recruitment of inflammatory cells (136-138).
TLR ligand activation with lipopolysaccharide (LPS) of EC resulted in the expression 
of TLR1, TLR3 and TLR4 and downstream production of IL-6 (139). A microarray 
gene ontology analysis of a two-dimensional culture model in vitro identified 24 
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over-represented genes in the TLR pathway after co-culture with EC (Study II). In 
the MSC/EC group both TLR3 and TLR4 were up-regulated which ultimately 
modulated the production of inflammatory cytokines. The pro-inflammatory cytokine 
IL-6 was down-regulated but IL-8, a chemoattractant and neutrophil activator (140),
was highly up-regulated in the MSC/EC group. The SuperArray analysis for the 
mouse TLR pathway after 3 weeks’ implantation in vivo showed down-regulation of 
TLR1, TLR2, TLR3, TLR4 and TLR8 in the EC constructs compared to the MSC 
constructs (Study III). The down-stream production of TLR was evaluated through
the release of inflammatory cytokines.
5.3.2 Release of inflammatory cytokines and inflammatory cell
recruitment
Copolymer scaffolds are biodegradable and serve as a temporary framework for 
tissue-engineered constructs (100). Scaffold degradation occurs in parallel with 
deposition of new matrix protein and recruitment of granulocytes, stem cells and 
monocyte-derived cells (141). This is an essential process of a foreign body giant cell 
reaction. Neutrophils are the first line of defense in acute inflammation and are later 
followed by monocyte-derived cells, T-cells and B-cells (64, 142, 143). Macrophages 
are broadly sub-divided into M1 and M2 phenotypes and they release pro-and anti-
inflammatory cytokines, respectively (144). Pro- and anti-inflammatory cytokines 
were evaluated after 1 week (Study II) and 3 weeks’ (Studies II and III)
implantation in vivo. A study done with different co-polymers showed no significant 
difference in inflammatory cell infiltration into the constructs after 2-4 weeks of 
implantation and also correlated inflammatory cells infiltration with angiogenesis 
(145). After 1 week, among all target genes only IL- -inflammatory cytokine 
was significantly down-regulated in MSC/EC constructs (146). Gene- and protein 
expression of IL- was down-regulated in MSC/EC (Study II) and EC (Study III)
constructs. The implantation of EC resulted in less IL-
cells. Despite decreased IL-
exponentially higher in constructs with EC. 
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IL-6 has been shown to have a dual function, with activation of IL-6 trans- and 
classic signaling resulting in pro- and anti-inflammatory function of IL-6,
respectively. Trans-signaling regulates switching of neutrophils to monocytes by 
regulating the different chemokines involved in neutrophil and monocyte chemo-
attraction (147-149). IL-6 can regulate the immunomodulatory property of MSC by 
inhibiting both dendritic cell differentiation and T-cell activation (150). MSC from 
IL-6 knockout mice were less efficient in resolving local swelling in an arthritic
mouse model. Additionally, MSC from wild type could suppress T-cell proliferation 
and could switch from Th1 to Th2 lymphocytes (151). The infiltration of monocyte-
derived cells, co-stained with IL-6 and CD11b, was decreased in constructs with EC.
The CD11b and IL-6 positive cells were seen in close proximity to the implanted 
scaffolds and degradation of the material was observed. Even though most of the cells 
were large and multinucleated, it was noted that MSC/EC constructs had fewer but
larger multinucleated giant cells associated. On the other hand, MSC constructs were
infiltrated with a greater number of smaller multinucleated cells (Study II). This 
specific pattern was not quantified. A longer in vivo experimental observation time 
would have helped to define the relation of these large cells in to the observed 
degradation profile of the scaffold. 
In the presence of EC, expression of the anti-inflammatory marker IL-10 was 
increased (Studies II and III). IL-10 inhibits the production of chemokines and pro-
inflammatory cytokines. It also regulates the extracellular matrix, fibroblast and EPC
and plays a vital role in tissue regeneration (152, 153). In IL-10 knockout mice, the 
survival and mobilization of EPC was reduced after myocardial infarction but after 
administration of IL-10 the number of EPC was increased and neovascularization was 
achieved (154).
NOS2 knockout mice showed impaired wound healing compared to wild type mice. 
Increased level of NOS2 could prevent the expansion of Th1 cells and help in immune 
suppression (155). NOS2 is an important regulator of MSC dependent T cell 
suppression. MSC from NOS2 knockout mice have shown decreased 
immunosuppression potential (92, 156). MSC transplantation along with NOS2 in 
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fibrotic livers in mice resulted in resolution of fibrosis with improved liver function 
and MSC survival compared to transplantation of MSC alone (157). NOS2 gene 
expression was comparatively higher in MSC/EC and EC constructs. Taken together, 
the above findings suggest that the presence of EC in the tissue-engineered construct
can improve regeneration by switching the cytokine expression of macrophages from 
the M1 to M2 phenotype.
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6. CONCLUDING REMARKS
The results of this series of studies suggest the following conclusions:
The secretomes released after hypoxic preconditioning of MSC and MSC/EC 
accelerated wound healing and promoted tube formation in vitro. Vasculogenic 
markers were up-regulated in the hypoxic groups compared to the normoxic 
groups.
The tissue-engineered constructs containing both MSC and EC recruited an 
increased number of neutrophils and decreased number of monocyte-derived cells,
which suggests a phase shift in the inflammatory response. Leukocyte 
transmigration into the tissue-engineered construct was greatly influenced by the 
addition of EC to the constructs. Mono-and co-culture constructs induced an
active immunogenic reaction compared to the control scaffold without cells.
EC influenced the hypoxic pathway and promoted vascularization in vivo.
Implantation of EC induced higher vascular density compared to implantation of 
MSC.
Implantation of MSC and EC altered the release of inflammatory cytokines. On 
addition of EC, up-regulation of anti-inflammatory cytokines and down-regulation 
of pro-inflammatory cytokines were observed, suggesting resolution of 
inflammation and initiation of tissue regeneration.
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7. FUTURE PERSPECTIVES
The present studies highlighted the vasculogenic and immunomodulatory properties
of MSC and EC. Further research is warranted to generate a large vascularized graft 
with long-lasting blood vessels for clinical applications. In depth research is needed 
to explore the inter-relationship between MSC and other cells, which communicate 
with MSC during the healing process.
By tracking the implanted human cells, we can identify the post-implantation survival 
of the cells and their integration with host tissues.
The results of these studies show alteration in recruitment of inflammatory cells after 
addition of EC. The role of co-culture and the paracrine effect of EC on MSC in
neutrophil quiescence and in the phase shift from M1 to M2 need further 
investigation.
The results of these studies also demonstrate the importance of EC in regenerating
vascularization, and future studies might include obtaining EPC and MSC from the
same donor to generate pre-vascularized construct for clinical use.
58
8. REFERENCES
1. Langer R, Vacanti JP. Tissue engineering. Science. 1993;260(5110):920-6.
2. Langer R, Vacanti J. Advances in tissue engineering. J Pediatr Surg. 
2016;51(1):8-12.
3. Sandor GK, Numminen J, Wolff J, Thesleff T, Miettinen A, Tuovinen VJ, et 
al. Adipose stem cells used to reconstruct 13 cases with cranio-maxillofacial hard-
tissue defects. Stem Cells Transl Med. 2014;3(4):530-40.
4. Rogers GF, Greene AK. Autogenous bone graft: basic science and clinical 
implications. J Craniofac Surg. 2012;23(1):323-7.
5. Murphy CM, O'Brien FJ, Little DG, Schindeler A. Cell-scaffold interactions in 
the bone tissue engineering triad. Eur Cell Mater. 2013;26:120-32.
6. Giannoudis PV, Einhorn TA, Schmidmaier G, Marsh D. The diamond 
concept--open questions. Injury. 2008;39 Suppl 2:S5-8.
7. Novosel EC, Kleinhans C, Kluger PJ. Vascularization is the key challenge in 
tissue engineering. Adv Drug Deliv Rev. 2011;63(4-5):300-11.
8. Cassell OC, Hofer SO, Morrison WA, Knight KR. Vascularisation of tissue-
engineered grafts: the regulation of angiogenesis in reconstructive surgery and in 
disease states. Br J Plast Surg. 2002;55(8):603-10.
9. Jain RK, Au P, Tam J, Duda DG, Fukumura D. Engineering vascularized 
tissue. Nat Biotechnol. 2005;23(7):821-3.
10. Eichmann A, Yuan L, Moyon D, Lenoble F, Pardanaud L, Breant C. Vascular 
development: from precursor cells to branched arterial and venous networks. Int J 
Dev Biol. 2005;49(2-3):259-67.
59
11. Laschke MW, Harder Y, Amon M, Martin I, Farhadi J, Ring A, et al. 
Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. 
Tissue Eng. 2006;12(8):2093-104.
12. Laschke MW, Menger MD. Vascularization in tissue engineering: 
angiogenesis versus inosculation. Eur Surg Res. 2012;48(2):85-92.
13. Shin'oka T, Imai Y, Ikada Y. Transplantation of a tissue-engineered pulmonary 
artery. N Engl J Med. 2001;344(7):532-3.
14. Hibino N, McGillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C, et 
al. Late-term results of tissue-engineered vascular grafts in humans. J Thorac 
Cardiovasc Surg. 2010;139(2):431-6, 6 e1-2.
15. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. 
Isolation of putative progenitor endothelial cells for angiogenesis. Science. 
1997;275(5302):964-7.
16. Kawamoto A, Losordo DW. Endothelial progenitor cells for cardiovascular 
regeneration. Trends Cardiovasc Med. 2008;18(1):33-7.
17. Krawiec JT, Vorp DA. Adult stem cell-based tissue engineered blood vessels: 
a review. Biomaterials. 2012;33(12):3388-400.
18. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4.
19. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu 
Rev Cell Dev Biol. 2011;27:563-84.
20. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease.
Nat Med. 1995;1(1):27-31.
21. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685-
93.
22. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-60.
60
23. Kalluri R. Basement membranes: structure, assembly and role in tumour 
angiogenesis. Nat Rev Cancer. 2003;3(6):422-33.
24. Pedersen TO, Blois AL, Xue Y, Xing Z, Sun Y, Finne-Wistrand A, et al. 
Mesenchymal stem cells induce endothelial cell quiescence and promote capillary 
formation. Stem Cell Res Ther. 2014;5(1):23.
25. Semenza GL. HIF-1: mediator of physiological and pathophysiological 
responses to hypoxia. J Appl Physiol (1985). 2000;88(4):1474-80.
26. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. 
Genes Cancer. 2011;2(12):1117-33.
27. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF 
system. Nat Med. 2003;9(6):677-84.
28. Folch A, Toner M. Microengineering of cellular interactions. Annu Rev 
Biomed Eng. 2000;2:227-56.
29. Fidkowski C, Kaazempur-Mofrad MR, Borenstein J, Vacanti JP, Langer R, 
Wang Y. Endothelialized microvasculature based on a biodegradable elastomer. 
Tissue Eng. 2005;11(1-2):302-9.
30. Kobayashi A, Miyake H, Hattori H, Kuwana R, Hiruma Y, Nakahama K, et al. 
In vitro formation of capillary networks using optical lithographic techniques. 
Biochem Biophys Res Commun. 2007;358(3):692-7.
31. Lee VK, Lanzi AM, Haygan N, Yoo SS, Vincent PA, Dai G. Generation of 
Multi-Scale Vascular Network System within 3D Hydrogel using 3D Bio-Printing 
Technology. Cell Mol Bioeng. 2014;7(3):460-72.
32. Wu PK, Ringeisen BR. Development of human umbilical vein endothelial cell 
(HUVEC) and human umbilical vein smooth muscle cell (HUVSMC) branch/stem 
structures on hydrogel layers via biological laser printing (BioLP). Biofabrication. 
2010;2(1):014111.
61
33. Laschke MW, Rucker M, Jensen G, Carvalho C, Mulhaupt R, Gellrich NC, et 
al. Improvement of vascularization of PLGA scaffolds by inosculation of in situ-
preformed functional blood vessels with the host microvasculature. Ann Surg. 
2008;248(6):939-48.
34. Laschke MW, Menger MD. Prevascularization in tissue engineering: Current 
concepts and future directions. Biotechnol Adv. 2016;34(2):112-21.
35. Warnke PH, Springer IN, Wiltfang J, Acil Y, Eufinger H, Wehmoller M, et al. 
Growth and transplantation of a custom vascularised bone graft in a man. Lancet. 
2004;364(9436):766-70.
36. Warnke PH, Wiltfang J, Springer I, Acil Y, Bolte H, Kosmahl M, et al. Man as 
living bioreactor: fate of an exogenously prepared customized tissue-engineered 
mandible. Biomaterials. 2006;27(17):3163-7.
37. Mesimaki K, Lindroos B, Tornwall J, Mauno J, Lindqvist C, Kontio R, et al. 
Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem 
cells. Int J Oral Maxillofac Surg. 2009;38(3):201-9.
38. Tatara AM, Wong ME, Mikos AG. In vivo bioreactors for mandibular 
reconstruction. J Dent Res. 2014;93(12):1196-202.
39. Lokmic Z, Mitchell GM. Engineering the microcirculation. Tissue Eng Part B 
Rev. 2008;14(1):87-103.
40. Mian R, Morrison WA, Hurley JV, Penington AJ, Romeo R, Tanaka Y, et al. 
Formation of new tissue from an arteriovenous loop in the absence of added 
extracellular matrix. Tissue Eng. 2000;6(6):595-603.
41. Eweida AM, Nabawi AS, Abouarab M, Kayed M, Elhammady H, Etaby A, et 
al. Enhancing mandibular bone regeneration and perfusion via axial vascularization 
of scaffolds. Clin Oral Investig. 2014;18(6):1671-8.
62
42. Eweida AM, Horch RE, Marei MK, Elhammady HA, Etaby AN, Nabawi AS, 
et al. Axially vascularised mandibular constructs: Is it time for a clinical trial? J 
Craniomaxillofac Surg. 2015;43(7):1028-32.
43. Baldwin J, Antille M, Bonda U, De-Juan-Pardo EM, Khosrotehrani K, 
Ivanovski S, et al. In vitro pre-vascularisation of tissue-engineered constructs A co-
culture perspective. Vasc Cell. 2014;6:13.
44. Wu X, Rabkin-Aikawa E, Guleserian KJ, Perry TE, Masuda Y, Sutherland 
FW, et al. Tissue-engineered microvessels on three-dimensional biodegradable 
scaffolds using human endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 
2004;287(2):H480-7.
45. Herrmann M, Binder A, Menzel U, Zeiter S, Alini M, Verrier S. CD34/CD133 
enriched bone marrow progenitor cells promote neovascularization of tissue 
engineered constructs in vivo. Stem Cell Res. 2014;13(3 Pt A):465-77.
46. Crivellato E, Nico B, Ribatti D. Contribution of endothelial cells to 
organogenesis: a modern reappraisal of an old Aristotelian concept. J Anat. 
2007;211(4):415-27.
47. Kirkpatrick CJ, Fuchs S, Unger RE. Co-culture systems for vascularization--
learning from nature. Adv Drug Deliv Rev. 2011;63(4-5):291-9.
48. Tremblay PL, Hudon V, Berthod F, Germain L, Auger FA. Inosculation of
tissue-engineered capillaries with the host's vasculature in a reconstructed skin 
transplanted on mice. Am J Transplant. 2005;5(5):1002-10.
49. Black AF, Berthod F, L'Heureux N, Germain L, Auger FA. In vitro 
reconstruction of a human capillary-like network in a tissue-engineered skin 
equivalent. FASEB J. 1998;12(13):1331-40.
50. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, et al. Lack 
of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J 
Cell Biol. 2001;153(3):543-53.
63
51. Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK. Tissue 
engineering: creation of long-lasting blood vessels. Nature. 2004;428(6979):138-9.
52. Darland DC, D'Amore PA. TGF beta is required for the formation of capillary-
like structures in three-dimensional cocultures of 10T1/2 and endothelial cells. 
Angiogenesis. 2001;4(1):11-20.
53. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem 
cells facilitate engineering of long-lasting functional vasculature. Blood. 
2008;111(9):4551-8.
54. Pedersen TO, Blois AL, Xing Z, Xue Y, Sun Y, Finne-Wistrand A, et al. 
Endothelial microvascular networks affect gene-expression profiles and osteogenic 
potential of tissue-engineered constructs. Stem Cell Res Ther. 2013;4(3):52.
55. Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat 
Med. 2006;12(2):171-2.
56. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and 
inflammation. Trends Immunol. 2006;27(12):552-8.
57. Newman AC, Hughes CC. Macrophages and angiogenesis: a role for Wnt 
signaling. Vasc Cell. 2012;4(1):13.
58. Hench LL, Thompson I. Twenty-first century challenges for biomaterials. J R 
Soc Interface. 2010;7 Suppl 4:S379-91.
59. Balint R, Cassidy NJ, Cartmell SH. Conductive polymers: towards a smart 
biomaterial for tissue engineering. Acta Biomater. 2014;10(6):2341-53.
60. Williams DF. On the mechanisms of biocompatibility. Biomaterials. 
2008;29(20):2941-53.
61. Williams DF. There is no such thing as a biocompatible material. Biomaterials. 
2014;35(38):10009-14.
64
62. Yu Y, Wu R-X, Yin Y, Chen F-M. Directing immunomodulation using 
biomaterials for endogenous regeneration. J Mater Chem B. 2016;4(4):569-84.
63. Sheikh Z, Brooks P, Barzilay O, Fine N, Glogauer M. Macrophages, Foreign 
Body Giant Cells and Their Response to Implantable Biomaterials. Materials. 
2015;8(9):5269.
64. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. 
Semin Immunol. 2008;20(2):86-100.
65. Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose 
and other tissues: basic biological properties and clinical applications. Stem Cells Int. 
2012;2012:461718.
66. Chen JY, Mou XZ, Du XC, Xiang C. Comparative analysis of biological 
characteristics of adult mesenchymal stem cells with different tissue origins. Asian 
Pac J Trop Med. 2015;8(9):739-46.
67. Ledesma-Martinez E, Mendoza-Nunez VM, Santiago-Osorio E. Mesenchymal 
Stem Cells Derived from Dental Pulp: A Review. Stem Cells Int. 
2016;2016:4709572.
68. Krebsbach PH, Kuznetsov SA, Bianco P, Robey PG. Bone marrow stromal 
cells: characterization and clinical application. Crit Rev Oral Biol Med.
1999;10(2):165-81.
69. Drost AC, Weng S, Feil G, Schafer J, Baumann S, Kanz L, et al. In vitro 
myogenic differentiation of human bone marrow-derived mesenchymal stem cells as 
a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci.
2009;1176:135-43.
70. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, 
et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. 
Stem Cells. 2004;22(3):377-84.
65
71. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, et al. 
Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular 
density, and improve heart function in a canine chronic ischemia model. Circulation. 
2005;111(2):150-6.
72. Janeczek Portalska K, Leferink A, Groen N, Fernandes H, Moroni L, van 
Blitterswijk C, et al. Endothelial differentiation of mesenchymal stromal cells. PloS 
One. 2012;7(10):e46842.
73. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, 
concepts, and assays. Cell Stem Cell. 2008;2(4):313-9.
74. Unger RE, Sartoris A, Peters K, Motta A, Migliaresi C, Kunkel M, et al. 
Tissue-like self-assembly in cocultures of endothelial cells and osteoblasts and the 
formation of microcapillary-like structures on three-dimensional porous biomaterials. 
Biomaterials. 2007;28(27):3965-76.
75. Brennan MA, Davaine JM, Layrolle P. Pre-vascularization of bone tissue-
engineered constructs. Stem Cell Res Ther. 2013;4(4):96.
76. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of 
human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-
derived MSC. Cell Commun Signal. 2011;9:12.
77. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A 
perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem 
Cell. 2008;3(3):301-13.
78. Chen CW, Montelatici E, Crisan M, Corselli M, Huard J, Lazzari L, et al. 
Perivascular multi-lineage progenitor cells in human organs: regenerative units, 
cytokine sources or both? Cytokine Growth Factor Rev. 2009;20(5-6):429-34.
79. Corselli M, Chen CW, Crisan M, Lazzari L, Peault B. Perivascular ancestors 
of adult multipotent stem cells. Arterioscler Thromb Vasc Biol. 2010;30(6):1104-9.
66
80. Caplan AI. All MSCs are pericytes? Cell Stem Cell. 2008;3(3):229-30.
81. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell.
2011;9(1):11-5.
82. Hoshino A, Chiba H, Nagai K, Ishii G, Ochiai A. Human vascular adventitial 
fibroblasts contain mesenchymal stem/progenitor cells. Biochem Biophys Res 
Commun. 2008;368(2):305-10.
83. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res. 
1996;32(4):687-98.
84. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: 
environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 
2013;45:e54.
85. Blocki A, Wang Y, Koch M, Peh P, Beyer S, Law P, et al. Not all MSCs can 
act as pericytes: functional in vitro assays to distinguish pericytes from other 
mesenchymal stem cells in angiogenesis. Stem Cells Dev. 2013;22(17):2347-55.
86. Mills SJ, Cowin AJ, Kaur P. Pericytes, mesenchymal stem cells and the wound 
healing process. Cells. 2013;2(3):621-34.
87. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal 
stem cells. Cell Death Differ. 2014;21(2):216-25.
88. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as 
guardians of inflammation. Mol Ther. 2012;20(1):14-20.
89. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. 
Annu Rev Pathol. 2011;6:457-78.
90. Li W, Ren G, Huang Y, Su J, Han Y, Li J, et al. Mesenchymal stem cells: a 
double-edged sword in regulating immune responses. Cell Death Differ. 
2012;19(9):1505-13.
67
91. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in 
immunomodulation: pathological and therapeutic implications. Nat Immunol. 
2014;15(11):1009-16.
92. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal 
stem cell-mediated immunosuppression occurs via concerted action of chemokines 
and nitric oxide. Cell Stem Cell. 2008;2(2):141-50.
93. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. 
J Clin Invest. 2012;122(3):787-95.
94. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. 
Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent 
reprogramming of host macrophages to increase their interleukin-10 production. Nat 
Med. 2009;15(1):42-9.
95. Krampera M. Mesenchymal stromal cell 'licensing': a multistep process. 
Leukemia. 2011;25(9):1408-14.
96. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells 
activity by toll-like receptors: implications on therapeutic potential. Mediators 
Inflamm. 2010;2010:865601.
97. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov 
A, Cohen S, et al. Toll-like receptors and their ligands control mesenchymal stem cell 
functions. Blood. 2007;109(4):1422-32.
98. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES,
Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their 
migration and immunomodulating responses. Stem Cells. 2008;26(1):99-107.
99. Odelius K, Plikk P, Albertsson AC. Elastomeric hydrolyzable porous 
scaffolds: copolymers of aliphatic polyesters and a polyether-ester. 
Biomacromolecules. 2005;6(5):2718-25.
68
100. Dånmark S, Finne-Wistrand A, Wendel M, Arvidson K, Albertsson A-C, 
Mustafa K. Osteogenic differentiation by rat bone marrow stromal cells on 
customized biodegradable polymer scaffolds. J Bioact Compat Polym. 
2010;25(2):207-23.
101. Xing Z, Xue Y, Danmark S, Schander K, Ostvold S, Arvidson K, et al. Effect 
of endothelial cells on bone regeneration using poly(L-lactide-co-1,5-dioxepan-2-
one) scaffolds. J Biomed Mater Res Part A. 2011;96(2):349-57.
102. Pfaffl MW. A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acid Res. 2001;29(9):e45.
103. Xue Y, Xing Z, Bolstad AI, Van Dyke TE, Mustafa K. Co-culture of human 
bone marrow stromal cells with endothelial cells alters gene expression profiles. The 
Int J Artif Organs. 2013;36(9):650-62.
104. Dysvik B, Jonassen I. J-Express: exploring gene expression data using Java. 
Bioinformatics. 2001;17(4):369-70.
105. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis 
of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-
57.
106. Chomczynski P, inventor; Google Patents, assignee. Shelf-stable product and 
process for isolating RNA, DNA and proteins. U S A Patent US5346994. 1993.
107. Carpentier G. ImageJ contribution: Angiogenesis Analyzer. ImageJ News. 
2012.
108. Chevalier F, Lavergne M, Negroni E, Ferratge S, Carpentier G, Gilbert-Sirieix 
M, et al. Glycosaminoglycan mimetic improves enrichment and cell functions of 
human endothelial progenitor cell colonies. Stem Cell Res. 2014;12(3):703-15.
69
109. Shimizu K, Ito A, Honda H. Enhanced cell-seeding into 3D porous scaffolds 
by use of magnetite nanoparticles. J Biomed Mater Res B Appl Biomater. 
2006;77(2):265-72.
110. Stiers PJ, van Gastel N, Carmeliet G. Targeting the hypoxic response in bone 
tissue engineering: A balance between supply and consumption to improve bone
regeneration. Mol Cell Endocrinol. 2016;432:96-105.
111. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 
2003;3(10):721-32.
112. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible 
factor 1. Crit Rev Oncol Hematol. 2006;59(1):15-26.
113. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 
1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-
proteasome pathway. Proc Natl Acad Sci U S A. 1998;95(14):7987-92.
114. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med.
2011;364(7):656-65.
115. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue 
regeneration. Regen Med. 2010;5(1):121-43.
116. Li Z, Wei H, Deng L, Cong X, Chen X. Expression and secretion of 
interleukin-1beta, tumour necrosis factor-alpha and interleukin-10 by hypoxia- and 
serum-deprivation-stimulated mesenchymal stem cells. FEBS J. 2010;277(18):3688-
98.
117. Lee DE, Ayoub N, Agrawal DK. Mesenchymal stem cells and cutaneous 
wound healing: novel methods to increase cell delivery and therapeutic efficacy. 
Stem Cell Res Ther. 2016;7(1):37.
70
118. Fujio M, Xing Z, Sharabi N, Xue Y, Yamamoto A, Hibi H, et al. Conditioned 
media from hypoxic-cultured human dental pulp cells promotes bone healing during 
distraction osteogenesis. J Tissue Eng Regen med. 2015.
119. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem 
cells recruit macrophages and endothelial lineage cells and enhance wound healing. 
PloS One. 2008;3(4):e1886.
120. Mayer H, Bertram H, Lindenmaier W, Korff T, Weber H, Weich H. Vascular 
endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: 
autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell 
Biochem. 2005;95(4):827-39.
121. Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Angiogenic 
effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt
pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and
stimulate angiogenesis. Stem Cells. 2007;25(9):2363-70.
122. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor 
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 
1992;359(6398):843-5.
123. Karar J, Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol
Neurosci. 2011;4:51.
124. Song R, Tian K, Wang W, Wang L. P53 suppresses cell proliferation, 
metastasis, and angiogenesis of osteosarcoma through inhibition of the 
PI3K/AKT/mTOR pathway. Int J Surg. 2015;20:80-7.
125. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances 
vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-
dependent signaling. FASEB J. 2002;16(8):771-80.
71
126. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-
inducible transcription factor depends primarily upon redox-sensitive stabilization of 
its alpha subunit. J Biol Chem. 1996;271(50):32253-9.
127. Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric 
oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res. 
2000;86(3):319-25.
128. Xue C, Rengasamy A, Le Cras TD, Koberna PA, Dailey GC, Johns RA. 
Distribution of NOS in normoxic vs. hypoxic rat lung: upregulation of NOS by 
chronic hypoxia. Am J Physiol. 1994;267(6 Pt 1):L667-78.
129. Brune B, Zhou J. The role of nitric oxide (NO) in stability regulation of 
hypoxia inducible factor-1alpha (HIF-1alpha). Curr Med Chem. 2003;10(10):845-55.
130. Chin LC, Kumar P, Palmer JA, Rophael JA, Dolderer JH, Thomas GP, et al. 
The influence of nitric oxide synthase 2 on cutaneous wound angiogenesis. Br J 
Dermatol. 2011;165(6):1223-35.
131. Mountziaris PM, Spicer PP, Kasper FK, Mikos AG. Harnessing and 
modulating inflammation in strategies for bone regeneration. Tissue Eng Part B Rev.
2011;17(6):393-402.
132. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or 
consequence? Angiogenesis. 2007;10(3):149-66.
133. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent 
B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-
scid mice. J Immunol. 1995;154(1):180-91.
134. Rennert RC, Sorkin M, Garg RK, Januszyk M, Gurtner GC. Cellular response 
to a novel fetal acellular collagen matrix: implications for tissue regeneration. Int J 
Biomater. 2013;2013:527957.
72
135. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new 
mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 
or an Immunosuppressive MSC2 phenotype. PloS One. 2010;5(4):e10088.
136. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, et al. Toll-like 
receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem 
cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. 
Stem Cells. 2008;26(1):279-89.
137. Romieu-Mourez R, Francois M, Boivin MN, Bouchentouf M, Spaner DE, 
Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal 
stromal cells leads to a proinflammatory phenotype. J Immunol. 2009;182(12):7963-
73.
138. Cassatella MA, Mosna F, Micheletti A, Lisi V, Tamassia N, Cont C, et al. 
Toll-like receptor-3-activated human mesenchymal stromal cells significantly 
prolong the survival and function of neutrophils. Stem Cells. 2011;29(6):1001-11.
139. Hijiya N, Miyake K, Akashi S, Matsuura K, Higuchi Y, Yamamoto S. Possible 
involvement of toll-like receptor 4 in endothelial cell activation of larger vessels in 
response to lipopolysaccharide. Pathobiology. 2002;70(1):18-25.
140. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional 
expression of a human interleukin-8 receptor. Science. 1991;253(5025):1278-80.
141. Amini AR, Wallace JS, Nukavarapu SP. Short-term and long-term effects of 
orthopedic biodegradable implants. J Long Term Eff Med Implants. 2011;21(2):93-
122.
142. Trindade R, Albrektsson T, Tengvall P, Wennerberg A. Foreign Body 
Reaction to Biomaterials: On Mechanisms for Buildup and Breakdown of 
Osseointegration. Clin Implant Dent Relat Res. 2014.
143. Ryan GB, Majno G. Acute inflammation. A review. Am J Pathol. 
1977;86(1):183-276.
73
144. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The 
chemokine system in diverse forms of macrophage activation and polarization. 
Trends Immunol. 2004;25(12):677-86.
145. Sung HJ, Meredith C, Johnson C, Galis ZS. The effect of scaffold degradation 
rate on three-dimensional cell growth and angiogenesis. Biomaterials. 
2004;25(26):5735-42.
146. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503-8.
147. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a 
regulator of the transition from neutrophil to monocyte recruitment during 
inflammation. Trends Immunol. 2003;24(1):25-9.
148. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto 
N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of 
leukocyte recruitment seen during acute inflammation. Immunity. 2001;14(6):705-14.
149. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-
inflammatory properties of the cytokine interleukin-6. Biochimica et biophysica acta. 
2011;1813(5):878-88.
150. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, 
et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an 
interleukin-6-dependent mechanism. Stem Cells. 2007;25(8):2025-32.
151. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D. IL-6-dependent PGE2 
secretion by mesenchymal stem cells inhibits local inflammation in experimental 
arthritis. PloS One. 2010;5(12):e14247.
152. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and 
the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
74
153. King A, Balaji S, Le LD, Crombleholme TM, Keswani SG. Regenerative 
Wound Healing: The Role of Interleukin-10. Adv Wound Care (New Rochelle). 
2014;3(4):315-23.
154. Krishnamurthy P, Thal M, Verma S, Hoxha E, Lambers E, Ramirez V, et al. 
Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell 
survival and function in ischemic myocardium. Circ Res. 2011;109(11):1280-9.
155. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, et al. Altered 
immune responses in mice lacking inducible nitric oxide synthase. Nature. 
1995;375(6530):408-11.
156. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide 
plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. 
Blood. 2007;109(1):228-34.
157. Ali G, Mohsin S, Khan M, Nasir GA, Shams S, Khan SN, et al. Nitric oxide 
augments mesenchymal stem cell ability to repair liver fibrosis. J Transl Med. 
2012;10:75.
